Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), É. Mateus Medina (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), S. Quirce Gancedo (Madrid, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain). PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial. 4784

Member's Comments

No comment yet.

Related content which might interest you: PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids Source: Eur Respir J, 50 (2) 1700670; 10.1183/13993003.00670-2017 Year: 2017 Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Source: Eur Respir J 2013; 41: 46-52 Year: 2013 The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003 The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Effect of the leukotriene-receptor antagonists and interval hypoxic trainings (IHT) at children with asthma (BA) and allergic rhinitis (AR) Source: Annual Congress 2008 - Exercise-induced asthma, acute severe asthma and allergic rhinitis in children Year: 2008 The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008 The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002 Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 Additional overall benefit to coexistent asthma and rhinitis symptoms control in patients treated with leukotriene receptor antagonist Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects Source: Eur Respir J 2007; 30: Suppl. 51, 490s Year: 2007 Salmeterol response is not affected by beta2-adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005 Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response Source: Eur Respir J 2003; 22: Suppl. 45, 204s Year: 2003 The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011 LATE-BREAKING ABSTRACT: Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The acute protective effect of a single dose of fluticasone propionate (FP) on the allergen-induced early asthmatic response in man Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002 Clinical efficacy of leukotriene antagonist in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005